🇺🇸 FDA
Patent

US 10604771

Delivery methods and compositions for nuclease-mediated genome engineering

granted A61KA61K35/28

Quick answer

US patent 10604771 (Delivery methods and compositions for nuclease-mediated genome engineering) held by Sangamo Therapeutics, Inc. expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K35/28